Hadassah Medical Center in partnership with the Israeli biotechnology company Kamada Ltd. in Jerusalem, Israel treated its first COVID-19 patient with what it described as a “passive vaccine.”1 Reportedly, a young female suffering from several underlying medical conditions, who had been hospitalized for several weeks and intubated, was passively vaccinated by injecting antibodies from a person who had recovered from COVID-19.2
What Is a “Passive Vaccine”?
According to The Jerusalem Post, passive vaccination is also known as immunoglobulin therapy or transfusion of convalescent plasma. For example, tetanus immune globulin is used to prevent tetanus infection (also known as lockjaw), which gives passive protection that lasts long enough until the patient’s body can produce its own antibodies against tetanus.3
Active vaccination to prevent a viral infection occurs when a person is injected with a live, attenuated or inactivated virus, which manipulates the immune system into thinking the patient has had the infectious disease and vaccine strain antibodies and artificial immunity are produced.4
First Hospital in the World to Administer Immunoglobulin G
At the beginning of the COVID-19 pandemic, Hadassah Medical Center began collecting plasma rich with antibodies from coronavirus patients who had recovered from the infection with the goal of producing a treatment for severely ill COVID-19 patients.5 The plasma collected from the recovered patients was processed by Kamada, Ltd. to produce an IgG-based antibody treatment for coronavirus patients in severe conditions.6
The first dose of the “passive vaccine” was provided to a young woman with a pre-existing medical condition whose computerized tomography (CT) scan showed white lungs, an indication that she was critically ill with the infection. All of the known treatments for coronavirus, including the use of an extracorporeal membrane oxygenation (ECMO) machine, had not improved her condition.7
Several hours after she received the immunoglobulin, it was observed that the patient’s condition stabilized, leading physicians to become cautiously optimistic.8
Kamada Announces Compassionate Use for Its IgG Therapy for COVID-19
In June 2020, Kamada completed manufacturing its first batch of a plasma-derived IgG product for COVID-19 utilizing the company’s proprietary IgG platform technology. Additional production is ongoing and the first vials are now available for compassionate use in Israel.9 Compassionate drug use is the use of a new, unapproved drug to treat a seriously ill patient when no other treatments are available.10
Kamada To Expand Its IgG Therapy to the United States
In order to expand its clinical development program to the U.S., Kamada, with the support of Kedrion Biopharma based in New Jersey, intends to conduct a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in order to obtain FDA’s approval of the proposed clinical development program.11
Kedrion is currently collecting COVID-19 convalescent plasma from U.S. recovered patients that will be used by Kamada to manufacture additional vials of the product. Kedrion is collecting the plasma through its plasma business unit, KEDPLASMA, at 23 FDA approved centers across the U.S.12
References:
1 Jaffe-Hoffman M. Hadassah treats COVID-19 patient with new concentrated passive vaccine. The Jerusalem Post June 24, 2020.
2 Ibid.
3 Mayo Clinic. Tetanus Immune Globulin. Feb. 1, 2020.
4 Ibid.
5 Stern A. Hadassah Hospital First in World to Test Passive Coronavirus Vaccine. Hamodia June 24, 2020.
6 Ibid.
7 Ibid.
8 Ibid.
9 Globe Newswire. Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel. BioSpace June 17, 2020.
10 U.S. Food and Drug Administration. Expanded Access. Apr. 27, 2020.
11 See Footnote 8.
12 Ibid.
10 Responses
This makes more sense than some of the other vaccines they’re coming up with. And wasn’t it an immunoglobulin shot that women used to have if they were exposed to Rubella and might be pregnant?
Excellent. Thank you Hadassah Medical Center, Kamada Ltd. Thank you to the patient for trying all options and The Jerusalem Post for gathering this information. This progress is welcomed. In addition to the use here for the recovery of critical care patients I hope this treatment offers a risk free option as an alternative to vaccine for those of us who prefer not to have a vaccine, as well. I hope this treatment obtains FDA approval.
This is actually nothing new. Prior to the availability of the Salk vaccine against polio, a family friend we had just visited developed polio a few days later. My sister and I both received gamma globulin shots. We did not develop polio.
Anything at all to do with vaccines involves nefarious agendas and individuals such as the Gates foundation. Wake up people!
Are there other ingredients in this?
I am fortunate to know of a food supplement that increases IgG in our bodies & therefore improving our immune system greatly. That, with Glycans, are the answer to protect cells & modulate our immune system.
The passive vaccine certainly sounds better than every other one they are testing with so many
toxic side effects causing more problems for us. I wouldn’t have any of them.Why are they trying to make vaccines mandatory -who does Gates think he is? In cahoots with Big Pharma. Heaven help us if they do make vaccinations mandatory which is already happening with the Flu vaccine if you want to visit loved ones in nursing homes, or send your child to school. We need to stand u for our own rights & not be told what to do.It’s our life.
what is really not clear is how those immunoglobulins are manufactured after collection of the original plasma. What does the process involve? what is in those injections beside the IgG?
This speaks for itself!
JULY 07, 2020 New Docs: NIH Owns Half of Moderna Vaccine
New documents obtained by Axios and Public Citizen suggest that the National Institute of Health (NIH) owns half the key patent for Moderna’s controversial COVID vaccine and could collect half the royalties. In addition, four NIH scientists have filed their own provisional patent application as co-inventors.
https://childrenshealthdefense.org/news/new-docs-nih-owns-half-of-moderna-vaccine/
You cannot develop immunity to tetanus. It’s a spore and not a transmittable disease. Tetanus spores are everywhere around us. Wounds that bleed will never result in tetanus because the tetanus bacillus is anaerobic.
“How can the Tetanus vaccine induce immunity, when contracting the disease naturally does not give immunity?”–NVIC
So if the model they are using is tetanus, it ain’t gonna work.
Just a short bit of information(simplified) : The vaccine for tetanus is not against the actual bacteria (Clostridium tetani) or its spores. C. tetani produces toxoids – one of which is tetanospasmin.This is a neurotoxin that interferes with release of neurotransmitters, blocking inhibitor impulses. This leads muscle contractions, spasms seizures and other symptoms, such as the classic “lockjaw.” Tetanospasmin is one of the most potent toxins known. The estimated minimum human lethal dose for a 70 kg human is only about 175 nanograms. The vaccine is actually an inactivated form of tetanospasmin. When vaccinated with the inactivated form of this neurotoxin, the body creates antibodies to the neurotoxin and the ability to make these antibodies is stored in “memory cells. If a person is later infected with C.tetani, the body “remembers” the assailing toxin. As a result of the previous vaccination, antibodies are produced which bind to the neurotoxin. This essentially inactivates the neurotoxin so that it cannot bind to receptors on neurons and prevent the release of neurotransmitters. The bacteria itself cannot survive in oxygen and is sensitive to heat. However the spores (endospores), which the bacteria create in order to survive stressful environments, are highly resistant to many chemical disinfectants and can survive autoclaving up to 121 C. When introduced into an “agreeable” environment (i.e. a puncture wound or dental abcess) the “spores” un-encapsulate and the bacteria can begin replicating and releasing the neurotoxins. One reason humans do not develop immunity to these neurotoxins without vaccination because the active toxin is so potent that an infected person usually dies before they can mount any sort of immune defense against it. Although, tetanus immunoglobulin can be used for a passive form of immunization if someone has not been vaccinated and is infected, it only works for as long as the passively introduced antibodies survive in the infected person. In that case, the person would probably also receive a vaccination at the same time that they are receiving the immunoglobulin. Passive immunization does not induce the body’s own cells to produce antibodies to the toxin. By the time you begin experiencing symptoms of tetanus, you already have a toxic level of neurotoxin floating around in your system. So if you have not been vaccinated, and the bacteria produce more toxin than can be controlled by whatever amount of immunoglobulin you are given within the amount of time that you have, you are sort of out of luck.